Moderna (NASDAQ:MRNA) Raised to Buy at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Moderna (NASDAQ:MRNA) from a hold rating to a buy rating in a research note published on Saturday morning. Zacks Investment Research currently has $15.00 target price on the stock.

According to Zacks, “Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company’s product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States. “

Other equities research analysts also recently issued research reports about the stock. Oppenheimer raised their price objective on shares of Moderna from $27.00 to $31.00 and gave the stock an outperform rating in a research note on Wednesday, May 29th. Piper Jaffray Companies raised their price objective on shares of Moderna from $24.00 to $30.00 and gave the stock an overweight rating in a research note on Wednesday, May 8th. Finally, Chardan Capital restated a buy rating and issued a $40.00 price objective on shares of Moderna in a research note on Sunday, June 2nd. Ten investment analysts have rated the stock with a buy rating, The company has an average rating of Buy and an average target price of $26.30.

NASDAQ:MRNA opened at $13.02 on Friday. Moderna has a 12 month low of $11.54 and a 12 month high of $29.79. The company has a market capitalization of $4.39 billion and a price-to-earnings ratio of -2.63. The company has a 50 day moving average price of $13.92.

About Moderna

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Further Reading: What is an Initial Public Offering (IPO)?

Get a free copy of the Zacks research report on Moderna (MRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Adobe  Issues Quarterly  Earnings Results
Adobe Issues Quarterly Earnings Results
Aduro BioTech Inc  CEO Sells $40,738.38 in Stock
Aduro BioTech Inc CEO Sells $40,738.38 in Stock
Trilogy International Partners Inc  Senior Officer Buys C$41,976.00 in Stock
Trilogy International Partners Inc Senior Officer Buys C$41,976.00 in Stock
FedEx  Issues Quarterly  Earnings Results, Misses Expectations By $0.12 EPS
FedEx Issues Quarterly Earnings Results, Misses Expectations By $0.12 EPS
Insider Selling: World Acceptance Corp.  SVP Sells $57,670.20 in Stock
Insider Selling: World Acceptance Corp. SVP Sells $57,670.20 in Stock
Prophecy Development Corp  Director Sells C$46,000.00 in Stock
Prophecy Development Corp Director Sells C$46,000.00 in Stock


© 2006-2019 Ticker Report